Selective Preservation of Pemetrexed Pharmacological Activity in HeLa Cells Lacking the Reduced Folate Carrier: Association with the Presence of a Secondary Transport Pathway

Rongbao Zhao, Marie Hanscom, Shrikanta Chattopadhyay, I. David Goldman

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

A methotrexate (MTX)-resistant HeLa subline (R5), developed in this laboratory, with impaired transport due to a genomic deletion of the reduced folate carrier (RFC) was only 2-fold resistant to pemetrexed (PMX), but 200- and 400-fold resistant to raltitrexed (ZD1694) and Nα -(-4-amino-4-deoxypteroyl)-Nδ-hemiphthaloy-1-ornithine (PT523), respectively, compared with parental HeLa cells when grown with 2 μM folic acid. When folic acid was replaced with the more physiological 25 nM 5-formyltetrahydrofolate, R5 cells were 2-fold collaterally sensitive to PMX but still 40- and 200-fold resistant to ZD1694 and PT523, respectively. Sensitivity to PT523 and PMX could be completely restored, and sensitivity to ZD1694 nearly restored, by transfection of RFC cDNA into R5 cells, indicating that the defect in drug transport was the only, or major, factor in resistance. The preserved PMX activity in R5 cells could not be related to the very low expression of folate receptors. Rather, retained PMX activity in R5 cells was associated with residual transport by another process that exhibits good affinity for PMX (Kt = 12 μM) with much lower affinities for ZD1694, MTX, and PT523 (Kis of ∼ 90, 100, and 250 μM, respectively). PMX transported by this route was rapidly converted to higher polyglutamates and, when grown with 25 nM 5-formyltetrahydrofolate, the rate of formation of these derivatives and their net accumulation in R5 cells was comparable to that of wild-type cells. These data suggest that selective preservation of PMX pharmacological activity in RFC-null R5 cells is due, in part, to partial preservation of transport by secondary process with a higher affinity for PMX than the other antifolates evaluated.

Original languageEnglish (US)
Pages (from-to)3313-3319
Number of pages7
JournalCancer Research
Volume64
Issue number9
DOIs
StatePublished - May 1 2004

Fingerprint

Pemetrexed
Reduced Folate Carrier Protein
HeLa Cells
Pharmacology
Folic Acid
Leucovorin
Methotrexate
Polyglutamic Acid
Folic Acid Antagonists
Null Lymphocytes
Ornithine
R Factors
Transfection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{772a63973b3e4d819466965745d2e086,
title = "Selective Preservation of Pemetrexed Pharmacological Activity in HeLa Cells Lacking the Reduced Folate Carrier: Association with the Presence of a Secondary Transport Pathway",
abstract = "A methotrexate (MTX)-resistant HeLa subline (R5), developed in this laboratory, with impaired transport due to a genomic deletion of the reduced folate carrier (RFC) was only 2-fold resistant to pemetrexed (PMX), but 200- and 400-fold resistant to raltitrexed (ZD1694) and Nα -(-4-amino-4-deoxypteroyl)-Nδ-hemiphthaloy-1-ornithine (PT523), respectively, compared with parental HeLa cells when grown with 2 μM folic acid. When folic acid was replaced with the more physiological 25 nM 5-formyltetrahydrofolate, R5 cells were 2-fold collaterally sensitive to PMX but still 40- and 200-fold resistant to ZD1694 and PT523, respectively. Sensitivity to PT523 and PMX could be completely restored, and sensitivity to ZD1694 nearly restored, by transfection of RFC cDNA into R5 cells, indicating that the defect in drug transport was the only, or major, factor in resistance. The preserved PMX activity in R5 cells could not be related to the very low expression of folate receptors. Rather, retained PMX activity in R5 cells was associated with residual transport by another process that exhibits good affinity for PMX (Kt = 12 μM) with much lower affinities for ZD1694, MTX, and PT523 (Kis of ∼ 90, 100, and 250 μM, respectively). PMX transported by this route was rapidly converted to higher polyglutamates and, when grown with 25 nM 5-formyltetrahydrofolate, the rate of formation of these derivatives and their net accumulation in R5 cells was comparable to that of wild-type cells. These data suggest that selective preservation of PMX pharmacological activity in RFC-null R5 cells is due, in part, to partial preservation of transport by secondary process with a higher affinity for PMX than the other antifolates evaluated.",
author = "Rongbao Zhao and Marie Hanscom and Shrikanta Chattopadhyay and Goldman, {I. David}",
year = "2004",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-03-3953",
language = "English (US)",
volume = "64",
pages = "3313--3319",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Selective Preservation of Pemetrexed Pharmacological Activity in HeLa Cells Lacking the Reduced Folate Carrier

T2 - Association with the Presence of a Secondary Transport Pathway

AU - Zhao, Rongbao

AU - Hanscom, Marie

AU - Chattopadhyay, Shrikanta

AU - Goldman, I. David

PY - 2004/5/1

Y1 - 2004/5/1

N2 - A methotrexate (MTX)-resistant HeLa subline (R5), developed in this laboratory, with impaired transport due to a genomic deletion of the reduced folate carrier (RFC) was only 2-fold resistant to pemetrexed (PMX), but 200- and 400-fold resistant to raltitrexed (ZD1694) and Nα -(-4-amino-4-deoxypteroyl)-Nδ-hemiphthaloy-1-ornithine (PT523), respectively, compared with parental HeLa cells when grown with 2 μM folic acid. When folic acid was replaced with the more physiological 25 nM 5-formyltetrahydrofolate, R5 cells were 2-fold collaterally sensitive to PMX but still 40- and 200-fold resistant to ZD1694 and PT523, respectively. Sensitivity to PT523 and PMX could be completely restored, and sensitivity to ZD1694 nearly restored, by transfection of RFC cDNA into R5 cells, indicating that the defect in drug transport was the only, or major, factor in resistance. The preserved PMX activity in R5 cells could not be related to the very low expression of folate receptors. Rather, retained PMX activity in R5 cells was associated with residual transport by another process that exhibits good affinity for PMX (Kt = 12 μM) with much lower affinities for ZD1694, MTX, and PT523 (Kis of ∼ 90, 100, and 250 μM, respectively). PMX transported by this route was rapidly converted to higher polyglutamates and, when grown with 25 nM 5-formyltetrahydrofolate, the rate of formation of these derivatives and their net accumulation in R5 cells was comparable to that of wild-type cells. These data suggest that selective preservation of PMX pharmacological activity in RFC-null R5 cells is due, in part, to partial preservation of transport by secondary process with a higher affinity for PMX than the other antifolates evaluated.

AB - A methotrexate (MTX)-resistant HeLa subline (R5), developed in this laboratory, with impaired transport due to a genomic deletion of the reduced folate carrier (RFC) was only 2-fold resistant to pemetrexed (PMX), but 200- and 400-fold resistant to raltitrexed (ZD1694) and Nα -(-4-amino-4-deoxypteroyl)-Nδ-hemiphthaloy-1-ornithine (PT523), respectively, compared with parental HeLa cells when grown with 2 μM folic acid. When folic acid was replaced with the more physiological 25 nM 5-formyltetrahydrofolate, R5 cells were 2-fold collaterally sensitive to PMX but still 40- and 200-fold resistant to ZD1694 and PT523, respectively. Sensitivity to PT523 and PMX could be completely restored, and sensitivity to ZD1694 nearly restored, by transfection of RFC cDNA into R5 cells, indicating that the defect in drug transport was the only, or major, factor in resistance. The preserved PMX activity in R5 cells could not be related to the very low expression of folate receptors. Rather, retained PMX activity in R5 cells was associated with residual transport by another process that exhibits good affinity for PMX (Kt = 12 μM) with much lower affinities for ZD1694, MTX, and PT523 (Kis of ∼ 90, 100, and 250 μM, respectively). PMX transported by this route was rapidly converted to higher polyglutamates and, when grown with 25 nM 5-formyltetrahydrofolate, the rate of formation of these derivatives and their net accumulation in R5 cells was comparable to that of wild-type cells. These data suggest that selective preservation of PMX pharmacological activity in RFC-null R5 cells is due, in part, to partial preservation of transport by secondary process with a higher affinity for PMX than the other antifolates evaluated.

UR - http://www.scopus.com/inward/record.url?scp=2342461116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342461116&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-3953

DO - 10.1158/0008-5472.CAN-03-3953

M3 - Article

C2 - 15126375

AN - SCOPUS:2342461116

VL - 64

SP - 3313

EP - 3319

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 9

ER -